GlassScriptPhysician profile
Olga Fedorenko
NPI 1669855029
$24,136.01
in general payments reported to CMS, 2019-2025
54 companies · $6,631 in 2025
The $6,631 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,150 · 2022: $3,787 · 2023: $3,980 · 2024: $5,588 · 2025: $6,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,198.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,727.01 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $2,188.90 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $1,910.20 | 2021-2025 | |
| Novo Nordisk INC | $1,523.40 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lundbeck LLC | $1,417.03 | 2023-2025 | Vyepti, Rexulti |
| Amgen INC. | $1,392.01 | 2022-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $1,285.50 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $1,279.74 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,047.75 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $954.45 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Janssen Pharmaceuticals, INC | $929.30 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $716.92 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $666.24 | 2021-2025 | Xifaxan, Trulance |
| Vanda Pharmaceuticals INC. | $604.24 | 2022-2025 | Fanapt, Hetlioz |
| Biohaven Pharmaceuticals, INC. | $587.53 | 2021 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $565.69 | 2023-2025 | Auvelity |
| Tolmar, INC. | $429.31 | 2023-2025 | Jatenzo |
| Sanofi-Aventis U.S. LLC | $426.78 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $341.07 | 2024-2025 | Rexulti |
| Inspire Medical Systems, INC. | $321.68 | 2024-2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $213.92 | 2023-2025 | Voquezna |
| Mylan Specialty L.P. | $182.10 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $180.79 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $175.14 | 2024-2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $161.42 | 2022-2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $145.20 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Idorsia Pharmaceuticals US INC | $135.77 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $129.75 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $107.86 | 2022 | |
| Antares Pharma, INC. | $105.60 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Cochlear Americas | $102.42 | 2024 | Baha, Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Ardelyx, INC. | $101.33 | 2024-2025 | Ibsrela |
| Paratek Pharmaceuticals, INC. | $94.12 | 2021-2025 | Nuzyra |
| Abiomed | $88.32 | 2024 | Impella |
| Lucid Diagnostics INC. | $86.16 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $83.83 | 2024 | |
| Astellas Pharma US INC | $72.31 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $69.91 | 2022-2023 | Belsomra, Gardasil 9, M-M-R II |
| Nestle Healthcare Nutrition INC. | $64.74 | 2022 | |
| Currax Pharmaceuticals LLC | $61.74 | 2022-2024 | Contrave |
| Bausch Health US, LLC | $57.51 | 2024-2025 | Wellbutrin, Aplenzin |
| Corium, LLC | $52.95 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $51.76 | 2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $50.42 | 2021-2025 | Eliquis |
| Myriad Women'S Health, INC. | $43.60 | 2023 | Myrisk |
| Teva Pharmaceuticals USA, INC. | $42.35 | 2021-2022 | |
| Corcept Therapeutics | $34.66 | 2024 | Korlym |
| Verona Pharma, INC. | $24.01 | 2025 | Ohtuvayre |
| Dexcom, INC. | $20.43 | 2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $19.84 | 2022 | |
| Janssen Scientific Affairs, LLC | $16.39 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.26 | 2025 | Jornay Pm |
| Acerus Pharmaceuticals Corporation | $14.55 | 2021 | |
| Amarin Pharma, INC. | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Fedorenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.